Because the glycans recognized by ACA, PHA-E+L, LCA, and SNA are known to be aberrantly expressed in several types of cancer, we selected these four lectins for the validation of differentially expressed glycans in our experimental cell lines. The gene discussed is LBR; the disease is cancer.